Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I clinical trial to assess the safety and immunogenicity of three HIV GTU MultiHIV DNA immunisations administered via the intramuscular, intradermal and transcutaneous routes in healthy male and female volunteers

Next Previous
X
Search
Trial Profile

A phase I clinical trial to assess the safety and immunogenicity of three HIV GTU MultiHIV DNA immunisations administered via the intramuscular, intradermal and transcutaneous routes in healthy male and female volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV DNA vaccine (Primary) ; HIV DNA vaccine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Acronyms CUT HIVAC Spoke 001

    • Most Recent Events

    • 19 Jul 2015 Status changed from recruiting to completed as per United Kingdom Clinical Research Network record.
    • 19 May 2014 New source Identified and integrated (ClinicalTrials.gov record: NCT02075983)
    • 27 Feb 2014 According to the ClinicalTrials.gov record, Planned End Date changed from 31 Jul 2014 to 1 Dec 2015.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top